The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1595
April 6, 2020
View Complete Issue         Table of Contents 2019 
Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta)
April 6, 2020 (Issue: 1595)
The FDA has approved two new drugs for sickle cell disease: crizanlizumab-tmca (Adakveo – Novartis), an IV P-selectin blocker, and voxelotor (Oxbryta – GBT), an oral hemoglobin S (HbS) polymerization inhibitor.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta)
Article code: 1595b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.